Human Infections with Borna Disease Virus 1 (BoDV-1) Primarily Lead to Severe Encephalitis: Further Evidence from the Seroepidemiological BoSOT Study in an Endemic Region in Southern Germany
Markus Bauswein,
Lisa Eidenschink,
Gertrud Knoll,
Bernhard Neumann,
Klemens Angstwurm,
Saida Zoubaa,
Markus J Riemenschneider,
Benedikt M J Lampl,
Matthias Pregler,
Hans Helmut Niller,
Jonathan Jantsch,
André Gessner,
Yvonne Eberhardt,
Gunnar Huppertz,
Torsten Schramm,
Stefanie Kühn,
Michael Koller,
Thomas Drasch,
Yvonne Ehrl,
Bernhard Banas,
Robert Offner,
Barbara Schmidt,
Miriam C. Banas
Affiliations
Markus Bauswein
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Lisa Eidenschink
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Gertrud Knoll
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Bernhard Neumann
Department of Neurology, Donau-Isar-Klinikum Deggendorf, 94469 Deggendorf, Germany
Klemens Angstwurm
Department of Neurology, University of Regensburg, Bezirksklinikum, 93053 Regensburg, Germany
Saida Zoubaa
Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany
Markus J Riemenschneider
Department of Neuropathology, University Hospital Regensburg, 93053 Regensburg, Germany
Benedikt M J Lampl
Regensburg Department of Public Health, 93059 Regensburg, Germany
Matthias Pregler
Regensburg Department of Public Health, 93059 Regensburg, Germany
Hans Helmut Niller
Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany
Jonathan Jantsch
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
André Gessner
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Yvonne Eberhardt
Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
Gunnar Huppertz
Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
Torsten Schramm
Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
Stefanie Kühn
Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
Michael Koller
Center for Clinical Studies, University Hospital Regensburg, 93053 Regensburg, Germany
Thomas Drasch
Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany
Yvonne Ehrl
Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany
Bernhard Banas
Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany
Robert Offner
Institute of Clinical Chemistry and Laboratory Medicine, Department of Transfusion Medicine, University Hospital Regensburg, 93053 Regensburg, Germany
Barbara Schmidt
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Miriam C. Banas
Department of Nephrology, University Hospital Regensburg, 93053 Regensburg, Germany
More than 40 human cases of severe encephalitis caused by Borna disease virus 1 (BoDV-1) have been reported to German health authorities. In an endemic region in southern Germany, we conducted the seroepidemiological BoSOT study (“BoDV-1 after solid-organ transplantation”) to assess whether there are undetected oligo- or asymptomatic courses of infection. A total of 216 healthy blood donors and 280 outpatients after solid organ transplantation were screened by a recombinant BoDV-1 ELISA followed by an indirect immunofluorescence assay (iIFA) as confirmatory test. For comparison, 288 serum and 258 cerebrospinal fluid (CSF) samples with a request for tick-borne encephalitis (TBE) diagnostics were analyzed for BoDV-1 infections. ELISA screening reactivity rates ranged from 3.5% to 18.6% depending on the cohort and the used ELISA antigen, but only one sample of a patient from the cohort with requested TBE diagnostics was confirmed to be positive for anti-BoDV-1-IgG by iIFA. In addition, the corresponding CSF sample of this patient with a three-week history of severe neurological disease tested positive for BoDV-1 RNA. Due to the iIFA results, all other results were interpreted as false-reactive in the ELISA screening. By linear serological epitope mapping, cross-reactions with human and bacterial proteins were identified as possible underlying mechanism for the false-reactive ELISA screening results. In conclusion, no oligo- or asymptomatic infections were detected in the studied cohorts. Serological tests based on a single recombinant BoDV-1 antigen should be interpreted with caution, and an iIFA should always be performed in addition.